Mediwound Ltd(MDWD) Finding the best opportunities to buy and sell stocks daily.

Sector:

Healthcare

Description:

MediWound Ltd. is a biopharmaceutical company engaging in the development, manufacture, and commercialization of products to address needs in the fields of severe burns, chronic wounds, and other hard-to-heal wounds. The firm focuses on developing, manufacturing and commercializing therapeutics products in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders and other indications. The firm's product, NexoBrid, is indicated for the removal of dead or damaged tissue, known as eschar, in adults with deep partial- and full-thickness thermal burns, also referred to as severe burns. The firm sells NexoBrid in Europe and Israel. NexoBrid is a topically-applied product that removes eschar in four hours without harming the surrounding healthy tissues. Its product, EscharEx, is a topical biological drug, which is being developed for debridement of chronic and other hard-to-heal wounds. NexoBrid and EscharEx are based on its proteolytic enzyme technology. The firm is also developing an injectable product based on its proteolytic enzyme technology for connective tissue pathologies and indications.

Current Price

$4.23

RSI

46.956

Beta:

1.578599

September 30, 2020

28.891 %
-69.649 %
32.861 %
-131.590 %

$31,789,000
$3,401,000
$2,496,000
$1,558,000
$601,000
$259,000
834.696 %
36.258 %
60.205 %
159.235 %
132.046 %

$2,066,000
$-5,665,000
$-14,533,000
$-18,885,000
$-21,671,000
$-18,875,000
374.201 %
156.540 %
29.946 %
14.752 %
-12.902 %

News

Press Releases

Notable Dates

All stock recommendations and comments are all opinions. Investors should be cautious about any and all stock recommendations and should consider the source of any advice on stock selection. Various factors, including personal ownership, may influence or factor into a stock analysis or opinion. All investors are advised to conduct their own independent research into individual stocks before making a purchase decision. In addition, investors are advised that past stock performance is not indicative of future price action.